Skip to main navigation Skip to search Skip to main content

A microRNA-based dynamic risk score for type 1 diabetes

  • Mugdha V. Joglekar
  • , Wilson K.M. Wong
  • , Pooja S. Kunte
  • , Hrishikesh P. Hardikar
  • , Reshmi A. Kulkarni
  • , Ryan J. Farr
  • , Ho Trong Nhan Pham
  • , Madilyn Coles
  • , Cody L. Maynard
  • , Riley Hayward
  • , Milan K. Piya
  • , Anandwardhan A. Hardikar
  • , Ritesh Chimoriya
  • , Caroline J. Taylor
  • , Maria Virginia Pereira E Cotta
  • , Nirupa Sachithanandan
  • , Charlotte X. Dong
  • , Fahmida K. Ema
  • , Sathya Perera
  • , Sarang N. Satoor
  • et al., PREDICT T1D Study Group
  • Western Sydney University
  • Campbelltown and Camden Hospitals
  • Roskilde University
  • La Trobe University

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)
4 Downloads (Pure)

Abstract

Identifying individuals at high risk of type 1 diabetes (T1D) is crucial as disease-delaying medications are available. Here we report a microRNA (miRNA)-based dynamic (responsive to the environment) risk score developed using multicenter, multiethnic and multicountry (‘multicontext’) cohorts for T1D risk stratification. Discovery (wet and dry lab) analysis identified 50 miRNAs associated with functional β cell loss, which is a hallmark of T1D. These miRNAs measured across n = 2,204 individuals from four contexts (4C: Australia, Denmark, Hong Kong SAR People’s Republic of China, India) led to a four-context, miRNA-based dynamic risk score (DRS) that effectively stratified individuals with and without T1D. Generative artificial intelligence was used to create an enhanced four-context, miRNA-based DRS, which offered good predictive power (area under the curve = 0.84) for T1D stratification in a separate multicontext validation dataset (n = 662), and accurately predicted future exogenous insulin requirement at 1 hour of islet transplantation. In a clinical trial assessing the imatinib drug therapy, baseline miRNA signature, rather than clinical characteristics, distinguished drug responders from nonresponders at 1 year. This study harnessed machine learning/generative artificial intelligence approaches, identifying and validating a miRNA-based DRS for T1D discrimination and treatment efficacy prediction.

Original languageEnglish
Pages (from-to)2622-2631
Number of pages10
JournalNature Medicine
Volume31
Issue number8
DOIs
Publication statusPublished - Aug 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'A microRNA-based dynamic risk score for type 1 diabetes'. Together they form a unique fingerprint.

Cite this